Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities: 2021-2024

Historic Total Non-Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $140.3 million.

  • Kiniksa Pharmaceuticals International's Total Non-Current Liabilities rose 39.62% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.4 million, marking a year-over-year increase of 39.62%. This contributed to the annual value of $140.3 million for FY2024, which is 63.85% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities stood at $140.3 million, which was up 63.85% from $85.6 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Total Non-Current Liabilities' 5-year high stood at $140.3 million during FY2024, with a 5-year trough of $47.5 million in FY2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Total Non-Current Liabilities value was $85.6 million (recorded in 2023), while the average stood at $95.9 million.
  • Data for Kiniksa Pharmaceuticals International's Total Non-Current Liabilities shows a peak YoY spiked of 63.85% (in 2024) over the last 5 years.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities (Yearly) stood at $47.5 million in 2021, then grew by 29.88% to $61.7 million in 2022, then surged by 38.81% to $85.6 million in 2023, then surged by 63.85% to $140.3 million in 2024.